January 16, 2026
Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge said Friday.
July 15, 2025
Biopharmaceutical company Biohaven Ltd. was hit with an investor suit claiming it overstated the odds that two of its product candidates would receive regulatory approval, hurting investors as it announced disappointing results.